ReviewSeminars in immunopathology2016
IgE and mast cells in host defense against parasites and venoms.
Review in Seminars in immunopathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 2 syntheses or guidelines pooled it, 191 citations in OpenAlex.
- Transcriptome-wide association study of circulating IgE levels identifies novel targets for asthma and allergic diseases.Frontiers in immunology · 2023Pooled it
- Evidence underscoring immunological and clinical pathological changes associated with Sarcoptes scabiei infection: synthesis and meta-analysis.BMC infectious diseases · 2022Pooled it
- Manipulation of host response and trajectory of parasite survival: A damage-response framework perspective.Virulence · 2026Review
- Review
- Pairing of high-mannose glycans in human IgE-Fc: implications for secretion and stability.Clinical proteomics · 2026Article
- Animals have expanded the evolutionary legacy of unicellular ancestors in blood cells.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Elucidating the relationship between affinity and potency in the performance of therapeutic IgE.Scientific reports · 2026Article
- Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy.Nature biomedical engineering · 2026Article
- Evaluation of the intraocular total IgE level and its ratio with serum IgE level for the diagnosis of ocular toxocariasis in children and adults: a retrospective comparative study.BMC ophthalmology · 2025Article
- Maternal IgE Influence on Fetal and Infant Health.Immunological reviews · 2025Review
- Structural and Functional Insights Into IgE Receptor Interactions and Disruptive Inhibition.Immunological reviews · 2025Review
- Inactivation of cofilin-1 in Mcpt5-Cre-nf-Cfl1Frontiers in immunology · 2025Article
- Reinventing type 2 immunity in cancer.Nature · 2025Review
- Epithelial-immune interactions govern type 2 immunity at barrier surfaces.Current opinion in immunology · 2024Review
- Paradoxical Worsening of Chronic Spontaneous Urticaria Following Omalizumab Administration: The Missing Link.Cureus · 2024Article
- Perioperative Pain Observation of Hip Fracture Surgery Patients with Cheek Acupuncture.Journal of pain research · 2024Article
- Associations between HLA class II alleles and IgE sensitization to allergens in the Qatar Biobank cohort.The journal of allergy and clinical immunology. Global · 2023Article
- Article
- Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.Nature communications · 2023Article
- Mast Cell Activation Syndrome Update-A Dermatological Perspective.Journal of personalized medicine · 2023Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
IgE-dependent mast cell activation is a major effector mechanism underlying the pathology associated with allergic disorders. The most dramatic of these IgE-associated disorders is the fatal anaphylaxis which can occur in some people who have developed IgE antibodies to otherwise innocuous antigens, such as those contained in certain foods and medicines. Why would such a highly "maladaptive" immune response develop in evolution and be retained to the present day? Host defense against parasites has long been considered the only beneficial function that might be conferred by IgE and mast cells. However, recent studies have provided evidence that, in addition to participating in host resistance to certain parasites, mast cells and IgE are critical components of innate (mast cells) and adaptive (mast cells and IgE) immune responses that can enhance host defense against the toxicity of certain arthropod and animal venoms, including enhancing the survival of mice injected with such venoms. Yet, in some people, developing IgE antibodies to insect or snake venoms puts them at risk for having a potentially fatal anaphylactic reaction upon subsequent exposure to such venoms. Delineating the mechanisms underlying beneficial versus detrimental innate and adaptive immune responses associated with mast cell activation and IgE is likely to enhance our ability to identify potential therapeutic targets in such settings, not only for reducing the pathology associated with allergic disorders but perhaps also for enhancing immune protection against pathogens and animal venoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.